Bempedoic Acid
In brief
- In our pharmacy, you can buy bempedoic acid without a prescription, with delivery across the United Kingdom and discreet, anonymous packaging.
- Bempedoic acid is used to lower LDLâcholesterol in adults with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet and maximally tolerated statin therapy, or as an option for statinâintolerant patients; it works by inhibiting ATP citrate lyase (ACL), reducing hepatic cholesterol synthesis upstream of HMGâCoA reductase.
- The usual dose is 180 mg orally once daily; a fixedâdose combination with ezetimibe is available as 180 mg/10 mg once daily for greater LDLâC reduction.
- It is administered as an oral filmâcoated tablet (bempedoic acid 180 mg) or as a fixedâdose combination tablet (180 mg/10 mg with ezetimibe).
- LDLâcholesterol lowering is generally measurable within about 2 weeks, with clinical reassessment typically at 4â12 weeks; it is not an immediate symptomatic treatment.
- The drug is taken once daily and provides around 24 hours of pharmacologic coverage; sustained LDLâC reduction requires continued longâterm daily use.
- Limit alcohol intake â avoid excessive alcohol as it may increase the risk of liver enzyme elevations and can worsen gout or hyperuricaemia; use caution in patients with hepatic impairment.
- The most common side effects include increased uric acid (hyperuricaemia) and gout, muscle spasms, back and limb pain, upper respiratory tract infections, abdominal pain, diarrhoea, fatigue and elevations in liver enzymes.
- Would you like to try bempedoic acid without a prescription?
Basic bempedoic acid information
- INN (international nonproprietary name): Bempedoic acid
- Brand names available in the United Kingdom: Nilemdo; Nustendi
- ATC code: C10AX15
- Forms and strengths: film-coated tablet 180 mg (monotherapy); film-coated tablet 180 mg/10 mg (fixed combination with ezetimibe, Nustendi)
- Manufacturers in the United Kingdom: Daiichi Sankyo (originator Esperion Therapeutics)
- Registration status in the United Kingdom: Licensed (Nilemdo, Nustendi)
- OTC / Rx classification: Prescription only (Rx)
Legal status and availability in the UK
In our online pharmacy, bempedoic acid is available without a prescription, with discreet delivery to the United Kingdom in 9â21 days.
Clinical effectiveness in the UK
Patients want to know how much LDLâC falls and whether the drug is tolerated better than statins.
- Typical LDLâC response: Meaningful reductions when added to maximally tolerated statin or when used alone in statinâintolerant patients.
- Tolerability: Usually better tolerated than statins in statinâintolerant patients, though some experience muscle spasms, raised uric acid or gastrointestinal upset.
NHS treatment pathways recommend reassessment at 4â12 weeks after initiation for LDLâC response and safety bloods including LFTs, uric acid and creatinine.
Indications and expanded uses (MHRA and NHS practice)
Patients commonly ask whether this is suitable for them and how clinicians are using it.
- Licensed indications
- Adults with primary hypercholesterolaemia or mixed dyslipidaemia.
- Common NHS uses
- Addâon to maximally tolerated statin where LDLâC targets are unmet; monotherapy for statinâintolerant adults.
- Offâlabel considerations
- Occasional use in specialist lipid clinics for selected familial hypercholesterolaemia patients where PCSK9 inhibitors are impractical or declined.
Clinicians must document rationale, obtain informed consent and set a monitoring plan under local governance arrangements.
Contraindications from product information include pregnancy and breastfeeding, known hypersensitivity and severe hepatic impairment.
Composition and brand landscape in the UK
People often want to know which brand they will receive and who supplies it.
| Brand name | Formulation | Manufacturer / licensee | Typical pack |
|---|---|---|---|
| Nilemdo | Bempedoic acid 180 mg tablet | Daiichi Sankyo Europe | 180 mg tablets in blisters |
| Nustendi | Bempedoic acid 180 mg / ezetimibe 10 mg tablet | Daiichi Sankyo Europe | 180 mg/10 mg tablets in blisters |
Electronic prescribing systems will list the licensed product name such as Nilemdo or Nustendi alongside the generic INN bempedoic acid.
Contraindications and special precautions (highârisk groups)
Patients frequently ask who should not take bempedoic acid and what to watch for.
Absolute contraindications: Known hypersensitivity to bempedoic acid or excipients; pregnancy and breastfeeding.
Relative contraindications / special cautions: Severe renal or hepatic impairment; history of gout or hyperuricaemia; prior tendon disorders or tendon rupture.
Elderly patients require routine monitoring although no standard dose adjustment is required based solely on age.
Advise patients who experience dizziness, fatigue or severe muscle symptoms to avoid driving or operating heavy machinery until assessed.
Record cautions in NHS electronic records and report suspected serious reactions via the MHRA Yellow Card system.
Dosage guidelines (NHS recommended regimens)
Patients ask how to take it and when to expect followâup.
| Situation | Recommended dose | Monitoring checkpoints |
|---|---|---|
| Standard adult (monotherapy) | 180 mg orally once daily | Baseline lipids, LFTs, creatinine, uric acid; reassess at 4â12 weeks |
| Fixed combination with ezetimibe | 180 mg / 10 mg orally once daily | Same baseline and 4â12 week reassessment |
| Renal impairment | No adjustment for mild/moderate (eGFR â„30) | Caution if eGFR <30; clinical data limited |
| Hepatic impairment | Not recommended in severe impairment | Use caution and monitor in moderate impairment |
Missed dose advice: take as soon as remembered unless it is close to the next dose; do not double up.
Overdose management is supportive; there is no specific antidote.
Interactions overview (drug, food and monitoring)
Patients commonly ask which medicines interact with bempedoic acid.
- Interaction burden: Relatively low compared with many lipid agents, but vigilance is required with other myotoxic medicines.
- Statins: Monitor for muscle symptoms when coâprescribed.
- Drugs that raise uric acid: Caution with agents that increase uric acid due to documented hyperuricaemia.
| Drug class / item | Action |
|---|---|
| Statins | Licensed to be coâprescribed; monitor for increased muscle symptoms and report via Yellow Card if serious. |
| Ezetimibe | Fixedâdose combination available (licensed). |
| Uricâacidâraising drugs | Use caution; monitor serum uric acid and manage gout risk. |
Encourage reporting of suspected interactions via the MHRA Yellow Card and documenting interactions in NHS records.
Comparable medicines and prescribing preferences (NHS alternatives)
Patients want to know how bempedoic acid compares with other options.
- Statins: Firstâline for most patients where tolerated; maximised before considering addâons.
- Ezetimibe: Wellâtolerated option often used before or together with bempedoic acid.
- PCSK9 inhibitors: Alirocumab and evolocumab are effective for very highârisk patients but their use is more restricted.
| Option | Pros | Cons |
|---|---|---|
| Bempedoic acid | Useful for statinâintolerant patients; fixed combination with ezetimibe available | Raised uric acid risk; monitoring for LFTs and uric acid required |
| Ezetimibe | Well tolerated; oral tablet | Less LDLâC lowering alone versus PCSK9 inhibitors |
| PCSK9 inhibitors | Large LDLâC reductions; strong evidence for highârisk patients | Injectable; access restrictions in NHS pathways |
Place in pathway: bempedoic acid is practical where statins are insufficient or not tolerated and when PCSK9 inhibitors are not indicated or accessible.
FAQs (common NHS patient questions)
Q: Will bempedoic acid replace my statin?
A: Usually not; it is an adjunct for those who cannot reach LDLâC goals with statins or who are statinâintolerant.
Q: What side effects should I watch for?
A: Report muscle pain, sudden joint or tendon pain, gout flares, jaundice or severe abdominal pain; routine blood tests monitor LFTs, creatinine and uric acid.
Q: Is it safe in pregnancy?
A: Contraindicated in pregnancy and breastfeeding; use reliable contraception and stop immediately if pregnancy is suspected.
Q: How quickly will my cholesterol fall?
A: NHS guidance reassesses LDLâC at 4â12 weeks; the degree of reduction depends on baseline therapy and whether ezetimibe is coâprescribed.
Pharmacy counselling checklist: confirm monitoring timetable, advise when to seek help and ensure followâup blood tests are arranged at 4â12 weeks.
Guidelines for proper use and pharmacist counselling (NHS style)
Pharmacists ask what to cover in a medication review and how to record it.
- Confirm indication: Note whether the patient is addâon to statin or statinâintolerant.
- Explain mechanism: Describe bempedoic acid as an ATP citrate lyase inhibitor distinct from statins.
- Outline dosing and monitoring: 180 mg once daily; baseline and 4â12 week blood checks for lipids, LFTs, creatinine and uric acid.
Use teachâback to confirm understanding and update NHS electronic records with monitoring plans and shared decision documentation.
Provide a short patient handout stating dose, common side effects and when to seek urgent advice.
Signpost patients to NHS.uk, local lipid clinics and the MHRA Yellow Card scheme for reporting adverse events.
Delivery across the United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 9â21 days |
| Birmingham | England | 9â21 days |
| Manchester | England | 9â21 days |
| Glasgow | Scotland | 9â21 days |
| Liverpool | England | 9â21 days |
| Leeds | England | 9â21 days |
| Sheffield | England | 9â21 days |
| Edinburgh | Scotland | 9â21 days |
| Bristol | England | 9â21 days |
| Newcastle | England | 9â21 days |
| Nottingham | England | 9â21 days |
| Coventry | England | 9â21 days |
| Cardiff | Wales | 9â21 days |
| Belfast | Northern Ireland | 9â21 days |
| Leicester | England | 9â21 days |
